In vivo positron emission tomography imaging of protease activity by generation of a hydrophobic product from a noninhibitory protease substrate

Keyphrases

• Tumor 100%
• Tetramethylrhodamine 100%
• Positron Emission Tomography 100%
• Hydrophobic Products 100%
• Protease Activity 100%
• Protease Substrate 100%
• Polyethylene Glycol 66%
• Matrix Metalloproteinases 66%
• Protease 50%
• Matrix metalloproteinase-2 (MMP-2) 50%
• HT1080 33%
• MCF-7 33%
• Prodrug 33%
• Targeted Therapy 33%
• MicroPET 33%
• HT-1080 Cells 33%
• MALDI-TOF 16%
• High Selectivity 16%
• Hydrophilicity 16%
• N-terminus 16%
• In Vivo Imaging 16%
• Peptide Substrate 16%
• Matrix Metalloproteinase Activity 16%
• After Injection 16%
• Prognosis Prediction 16%
• Patient Prognosis 16%
• Labeled Probes 16%
• Image Matrix 16%
• Hydrophilic Peptides 16%
• MCF-7 Cells 16%
• Imaging Technology 16%
• 18F-labeled 16%

Neuroscience

• In Vivo 100%
• Proteinase 100%
• Positron Emission Tomography 100%
• Fluorine-18 71%
• Matrix Metalloproteinase 71%
• Macrogol 57%
• MMP2 42%
• Positron Emission Tomography 28%
• Prodrug 28%
• In Vitro 14%
• Amino Terminal Sequence 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Proteinase 100%
• Neoplasm 85%
• Tetramethylrhodamine 85%
• Matrix Metalloproteinase 71%
• Fluorine 18 71%
• Macrogol 57%
• Gelatinase A 42%
• Prodrug 28%
• Polyethylene Terephthalate 28%
• Matrix-Assisted Laser Desorption/Ionization 14%